10 Best Medical Research Stocks to Buy According to Hedge Funds

8. Amgen Inc. (NASDAQ:AMGN)

Number of Hedge Fund Holders: 62

Amgen Inc. (NASDAQ:AMGN) is one of the best medical research stocks to buy according to hedge funds. Amgen Inc. (NASDAQ:AMGN) received rating updates from Argus Research and Guggenheim on February 6. Argus reiterated a Buy rating on the stock with a $400 price target, while Guggenheim reaffirmed a Hold rating on Amgen Inc. (NASDAQ:AMGN) and set a price target of $347.

The rating updates came after Amgen Inc. (NASDAQ:AMGN) reported its fiscal Q4 and full year 2025 results on February 3, announcing strong performance in 2025 with double-digit growth in revenues and EPS. Total revenues for fiscal Q4 rose 9% to $9.9 billion compared to the prior year period, with product sales growing 7%, driven by 10% volume growth. Total revenues for the full year reached $36.8 billion, up 10% compared to the same quarter last year.

Amgen Inc. (NASDAQ:AMGN) further reported that product sales grew 10%, driven by 13% volume growth, partially offset by 3% lower net selling price. 18 of the company’s products attained record sales for the full year, while 14 products exceeded one billion dollars in annual sales. Amgen Inc. (NASDAQ:AMGN) expects total revenues in the $37.0 billion to $38.4 billion range for the full year 2026.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.